PMID- 8948369
OWN - NLM
STAT- MEDLINE
DCOM- 19961220
LR  - 20191024
IS  - 1077-9450 (Print)
IS  - 1077-9450 (Linking)
VI  - 13
IP  - 4
DP  - 1996 Dec 1
TI  - CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
PG  - 320-6
AB  - CD8+ T lymphocytes may mediate important host responses to human immunodeficiency 
      virus (HIV) infection by human leukocyte antigen (HLA)-restricted cytotoxicity 
      and production of soluble HIV suppressor factors. CD8+ lymphocytes are also 
      important for the suppression of many latent pathogens responsible for 
      opportunistic disease in HIV-infected patients. There has been no systematic 
      analysis of the responses of CD8+ lymphocyte counts to antiretroviral therapy. We 
      compared CD8+ lymphocyte responses in seven trials of nucleoside or 
      non-nucleoside analog reverse transcriptase inhibitors and in two trials of 
      ritonavir, a HIV protease inhibitor. Nucleoside analog and non-nucleoside analog 
      reverse transcriptase inhibitor monotherapy resulted in no substantial changes in 
      CD8+ counts relative to baseline or placebo. Combination nucleoside analog 
      therapy resulted in variable peak responses (-145 to +240 cells/mm3), which 
      remained significantly above baseline for 0 to 12 weeks. In contrast, ritonavir 
      monotherapy caused a peak increase of 892 CD8+ cells/mm3, which remained 
      significantly above baseline for 32 weeks. There was a significant correlation 
      (Rs 0.61, p = 0.01) between the peak CD4+ cell and CD8+ responses to each 
      therapy, but no significant correlation between the peak viral load responses and 
      peak CD8+ cell responses. These findings suggest that the greater CD8+ response 
      seen with ritonavir may be due to its specific inhibition of HIV protease and 
      also that the CD8+ response is dependent on new CD4+ cell production. The CD8+ 
      lymphocyte proliferation observed with protease inhibitor therapy could result in 
      improved suppression of HIV replication by the immune system and should be 
      confirmed in a prospective trial comparing protease inhibitors with both 
      nucleoside and non-nucleoside analog therapies.
FAU - Carr, A
AU  - Carr A
AD  - HIV Medicine Unit, St. Vincent's Hospital, Sydney, Australia.
FAU - Emery, S
AU  - Emery S
FAU - Kelleher, A
AU  - Kelleher A
FAU - Law, M
AU  - Law M
FAU - Cooper, D A
AU  - Cooper DA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acquir Immune Defic Syndr Hum Retrovirol
JT  - Journal of acquired immune deficiency syndromes and human retrovirology : 
      official publication of the International Retrovirology Association
JID - 9501482
RN  - 0 (Acetamides)
RN  - 0 (Acetophenones)
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 3S1R1LZ09H (loviride)
RN  - 4B9XT59T7S (Zidovudine)
RN  - 6L3XT8CB3I (Zalcitabine)
RN  - CI9X00489L (2',3'-dideoxycytidinene)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - K3GDH6OH08 (Didanosine)
RN  - O3J8G9O825 (Ritonavir)
SB  - IM
CIN - J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jun 1;15(2):176-7. PMID: 9241121
CIN - J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):391-3. PMID: 9704947
MH  - Acetamides/therapeutic use
MH  - Acetophenones/therapeutic use
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Didanosine/therapeutic use
MH  - Drug Therapy, Combination
MH  - HIV Infections/drug therapy/*immunology/virology
MH  - HIV Protease Inhibitors/*therapeutic use
MH  - HIV Reverse Transcriptase/antagonists & inhibitors
MH  - Humans
MH  - Lamivudine/therapeutic use
MH  - Lymphocyte Count
MH  - Pyridines/therapeutic use
MH  - Reverse Transcriptase Inhibitors/*therapeutic use
MH  - Ritonavir/therapeutic use
MH  - Viral Load
MH  - Zalcitabine/analogs & derivatives/therapeutic use
MH  - Zidovudine/therapeutic use
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1097/00042560-199612010-00004 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 1;13(4):320-6. doi: 
      10.1097/00042560-199612010-00004.